Biogen

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,500

Employees7,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,500

Employees7,500

BIIB Key Statistics

Market cap

33.16B

Market cap33.16B

Price-Earnings ratio

39.43

Price-Earnings ratio39.43

Dividend yield

—

Dividend yield—

Average volume

722.34K

Average volume722.34K

High today

$225.80

High today$225.80

Low today

$221.23

Low today$221.23

Open price

$225.80

Open price$225.80

Volume

549.27K

Volume549.27K

52 Week high

$225.80

52 Week high$225.80

52 Week low

$135.39

52 Week low$135.39

Stock Snapshot

The current Biogen(BIIB) stock price is $224.51, with a market capitalization of 33.16B. The stock trades at a price-to-earnings (P/E) ratio of 39.43.

During the trading session on 2026-09-03, Biogen(BIIB) shares reached a daily high of $225.80 and a low of $221.23. At a current price of $224.51, the stock is +1.5% higher than the low and still -0.6% under the high.

Trading volume for Biogen(BIIB) stock has reached 549.27K, versus its average volume of 722.34K.

The stock's 52-week range extends from a low of $135.39 to a high of $225.80.

BIIB News

Investing.com 7h

Piper Sandler raises Biogen stock price target on pipeline outlook - Investing.com

...

TipRanks 11h

Biogen price target raised to $245 from $225 at Piper Sandler

Piper Sandler raised the firm’s price target on Biogen (BIIB) to $245 from $225 and keeps an Overweight rating on the shares. The firm cites post-Q2 model updat...

TipRanks 11h

Biogen, Eisai announce NMPA of China approves subcutaneous Leqembi

Eisai (ESAIY) and Biogen (BIIB) announced that the National Medical Products Administration of China has approved the subcutaneous formulation, the anti-amyloid...

Analyst ratings

67%

of 36 ratings

Buy

66.7%

Hold

30.6%

Sell

2.8%

More BIIB News

Simply Wall St 21h

How Biogen’s At-Home LEQEMBI Injections Could Reframe the Alzheimer’s Treatment Investment Story

In August 2026, Eisai and Biogen announced that once-weekly LEQEMBI IQLIK subcutaneous injections are now available in the U.S. for at-home initiation and maint...

TipRanks 2d

Stoke Therapeutics, Biogen present clinical data of Dravet syndrome candidate

Stoke Therapeutics (STOK) and Biogen (BIIB) announced presentations of data at the 16th European Epilepsy Congress September 5-9 in Athens. These data support t...

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.